OverviewSuggest Edit

Harrow Health (formerly Imprimis Pharmaceuticals) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It also owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

TypePublic
Founded2012
HQSan Diego, CA, US
Websiteharrowinc.com

Latest Updates

Employees (est.) (Mar 2020)133
Job Openings24
Revenue (FY, 2020)$48.9 M(-4%)
Share Price (Apr 2021)$7 (+4%)
Cybersecurity ratingAMore

Key People/Management at Harrow Health

Mark L. Baum

Mark L. Baum

Chief Executive Officer, Member, Board of Directors
Andrew R. Boll

Andrew R. Boll

CFO
John Saharek

John Saharek

Chief Commercial Officer
Show more

Harrow Health Office Locations

Harrow Health has offices in San Diego, Irvine, Nashville and Roxbury Township
San Diego, CA, US (HQ)
12264 El Camino Real #350
Irvine, CA, US
9257 Research Dr
Nashville, TN, US
102 Woodmont Blvd #610
Roxbury Township, NJ, US
1705 US-46 #6b, Ledgewood
Show all (4)

Harrow Health Financials and Metrics

Harrow Health Revenue

Harrow Health's revenue was reported to be $48.87 m in FY, 2020
USD

Revenue (FY, 2020)

48.9m

Gross profit (FY, 2020)

34.4m

Gross profit margin (FY, 2020), %

70.4%

Net income (FY, 2020)

(3.4m)

EBIT (FY, 2020)

385.0k

Market capitalization (7-Apr-2021)

181.1m

Closing stock price (7-Apr-2021)

7.0

Cash (31-Dec-2020)

4.1m

EV

200.5m
Harrow Health's current market capitalization is $181.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

100.0k10.0k1.7m9.7m19.9m26.8m41.4m51.2m48.9m

Revenue growth, %

485%105%

Cost of goods sold

16.5m16.7m14.5m

Gross profit

24.9m34.4m34.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

100.0k2.5k2.5k2.5k1.4k667.7k441.0k1.6m2.0m2.7m4.4m4.9m4.9m6.1m6.9m6.5m8.9m10.4m10.7m12.3m13.5m12.8m11.8m8.1m

Cost of goods sold

4.2m4.2m3.9m5.2m4.1m3.6m3.2m

Gross profit

6.2m6.5m8.4m8.3m8.7m8.2m4.9m

Gross profit Margin, %

60%61%68%61%68%69%60%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

146.2k10.0m15.6m8.2m2.7m8.9m4.0m6.8m4.9m4.1m

Accounts Receivable

81.3k840.0k2.9m1.5m1.9m2.0m2.7m

Prepaid Expenses

14.8k61.6k105.1k240.4k786.0k714.0k837.0k1.3m751.0k

Inventories

372.7k1.4m1.8m2.2m1.8m3.3m4.0m
USDQ2, 2011

Financial Leverage

-0.1 x
Show all financial metrics

Harrow Health Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Harrow Health Online and Social Media Presence

Embed Graph

Harrow Health News and Updates

Harrow Health to Participate in H.C. Wainwright Global Life Sciences Conference

NASHVILLE, Tenn., March 02, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright Global Life Sciences Confere…

Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021

NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020, on Monday, March 8, 2021, after the Nasdaq market cl…

Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference

NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow’s Chief Executive Officer, and Andrew Boll, Harrow’s Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place D…

Harrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020

NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 financial results and host a conference call at 4:45 p.m. Eastern Standard Time / 1:45 p.m. Pacific…

Harrow Health Appoints Larry Van Horn to its Board of Directors

NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors.

Harrow Health to Announce Second Quarter 2020 Financial Results on August 10, 2020

NASHVILLE, Tenn., July 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific…
Show more

Harrow Health Blogs

Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results

Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results

Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal

Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal

Harrow Health Publishes Third Quarter 2020 Letter to Stockholders

Harrow Health Publishes Third Quarter 2020 Letter to Stockholders

Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020

Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020

Harrow Health Publishes Second Quarter 2020 Letter to Stockholders

Harrow Health Publishes Second Quarter 2020 Letter to Stockholders

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®
Show more

Harrow Health Frequently Asked Questions

  • When was Harrow Health founded?

    Harrow Health was founded in 2012.

  • Who are Harrow Health key executives?

    Harrow Health's key executives are Mark L. Baum, Andrew R. Boll and John Saharek.

  • How many employees does Harrow Health have?

    Harrow Health has 133 employees.

  • What is Harrow Health revenue?

    Latest Harrow Health annual revenue is $48.9 m.

  • What is Harrow Health revenue per employee?

    Latest Harrow Health revenue per employee is $367.5 k.

  • Who are Harrow Health competitors?

    Competitors of Harrow Health include Cour Pharmaceuticals Development, Zhimeng Biopharma and CuraSen Therapeutics.

  • Where is Harrow Health headquarters?

    Harrow Health headquarters is located at 12264 El Camino Real #350, San Diego.

  • Where are Harrow Health offices?

    Harrow Health has offices in San Diego, Irvine, Nashville and Roxbury Township.

  • How many offices does Harrow Health have?

    Harrow Health has 4 offices.